Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 6/2017

24.10.2017 | Acute Myeloid Leukemias (H Erba, Section Editor)

Diagnostic and Prognostic Utility of Fluorescence In situ Hybridization (FISH) Analysis in Acute Myeloid Leukemia

verfasst von: Patrick R. Gonzales, Fady M. Mikhail

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Acute myeloid leukemia (AML) is a hematologic neoplasia consisting of incompletely differentiated hematopoietic cells of the myeloid lineage that proliferate in the bone marrow, blood, and/or other tissues. Clinical implementation of fluorescence in situ hybridization (FISH) in cytogenetic laboratories allows for high-resolution analysis of recurrent structural chromosomal rearrangements specific to AML, especially in AML with normal karyotypes, which comprises approximately 33–50% of AML-positive specimens. Here, we review the use of several FISH probe strategies in the diagnosis of AML. We also review the standards and guidelines currently in place for use by clinical cytogenetic laboratories in the evaluation of AML.

Recent Findings

Updated standards and guidelines from the WHO, ACMG, and NCCN have further defined clinically significant, recurring cytogenetic anomalies in AML that are detectable by FISH.

Summary

FISH continues to be a powerful technique in the diagnosis of AML, with higher resolution than conventional cytogenetic analysis, rapid turnaround time, and a considerable diagnostic and prognostic utility.
Literatur
1.
Zurück zum Zitat Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.CrossRefPubMed Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.CrossRefPubMed
2.
Zurück zum Zitat Gersen SL, Keagle MB, editors. The principles of clinical cytogenetics. 3rd ed. New York City: Springer; 2013. Gersen SL, Keagle MB, editors. The principles of clinical cytogenetics. 3rd ed. New York City: Springer; 2013.
3.
Zurück zum Zitat Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal hematopoiesis to secondary leukemia. Nat Rev Cancer. 2017;17:5–19.CrossRefPubMed Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal hematopoiesis to secondary leukemia. Nat Rev Cancer. 2017;17:5–19.CrossRefPubMed
4.
Zurück zum Zitat Barrett R, Morash B, Roback D, Pambrun C, Marfleet L, Ketterling RP, et al. FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype. Pediatr Blood Cancer. 2017:1–4. Barrett R, Morash B, Roback D, Pambrun C, Marfleet L, Ketterling RP, et al. FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype. Pediatr Blood Cancer. 2017:1–4.
5.
Zurück zum Zitat Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:1–7. Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:1–7.
6.
Zurück zum Zitat Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058–66.CrossRefPubMedPubMedCentral Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058–66.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed
8.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed
9.
Zurück zum Zitat Mikhail FM, Heerema NA, Rao KW, Burnside RD, Cherry AM, Cooley LD, et al. Section E6.1–6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow–acquired chromosomal abnormalities. Genet Med. 2016;18:635-42. Mikhail FM, Heerema NA, Rao KW, Burnside RD, Cherry AM, Cooley LD, et al. Section E6.1–6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow–acquired chromosomal abnormalities. Genet Med. 2016;18:635-42.
10.
Zurück zum Zitat Zneimer SM. Cytogenetic abnormalities: chromosomal, FISH and microarray-based clinical reporting. Hoboken: John Wiley & Sons, Inc.; 2014.CrossRef Zneimer SM. Cytogenetic abnormalities: chromosomal, FISH and microarray-based clinical reporting. Hoboken: John Wiley & Sons, Inc.; 2014.CrossRef
11.
Zurück zum Zitat Sholl LM, Longtine J, Kuo FC. Molecular analysis of gene rearrangements and mutations in acute leukemias and myeloid neoplasms. Curr Protoc Hum Genet. 2017;92:10.4.1–10.4.49.CrossRef Sholl LM, Longtine J, Kuo FC. Molecular analysis of gene rearrangements and mutations in acute leukemias and myeloid neoplasms. Curr Protoc Hum Genet. 2017;92:10.4.1–10.4.49.CrossRef
12.
Zurück zum Zitat Mascarello JT, Hirsch B, Kearney HM, Ketterling RP, Olson SB, Quigley DI, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13:667–75.CrossRefPubMed Mascarello JT, Hirsch B, Kearney HM, Ketterling RP, Olson SB, Quigley DI, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13:667–75.CrossRefPubMed
14.
Zurück zum Zitat Sasine JP, Schiller GJ. Acute myeloid leukemia: how do we measure success? Curr Hematol Malig Rep. 2016;11:528–36.CrossRefPubMed Sasine JP, Schiller GJ. Acute myeloid leukemia: how do we measure success? Curr Hematol Malig Rep. 2016;11:528–36.CrossRefPubMed
15.
Zurück zum Zitat Gowan-Jordan J, Simons A, Schmid M, editors. ISCN 2016 an international system for human Cytogenomic nomenclature (2016). Basel: S. Karger AG; 2016. Gowan-Jordan J, Simons A, Schmid M, editors. ISCN 2016 an international system for human Cytogenomic nomenclature (2016). Basel: S. Karger AG; 2016.
16.
Zurück zum Zitat Ley TJ. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.CrossRefPubMed Ley TJ. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.CrossRefPubMed
18.
Zurück zum Zitat Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, et al. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood. 2017;129:1333–42.CrossRefPubMed Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, et al. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood. 2017;129:1333–42.CrossRefPubMed
19.
Zurück zum Zitat Ney Garcia DR, De Souza MT, De Figueiredo AF, Othman MAK, Rittscher K, Abdelhay E, et al. Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes. Hematol Oncol. 2016:1–9. Ney Garcia DR, De Souza MT, De Figueiredo AF, Othman MAK, Rittscher K, Abdelhay E, et al. Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes. Hematol Oncol. 2016:1–9.
20.
Zurück zum Zitat Valentine M, Linabery A, Chasnoff S, Hughes A, Mallaney C, Sanchez N, et al. Excess congenital non-synonymous variation in leukemia-associated genes in MLL-infant leukemia: a Children’s Oncology Group report. Leukemia. 2014;28:1235–41.CrossRefPubMedPubMedCentral Valentine M, Linabery A, Chasnoff S, Hughes A, Mallaney C, Sanchez N, et al. Excess congenital non-synonymous variation in leukemia-associated genes in MLL-infant leukemia: a Children’s Oncology Group report. Leukemia. 2014;28:1235–41.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Shigesada K, van de Sluis B, Liu PP. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MYH11. Oncogene. 2004;23:4297–307.CrossRefPubMed Shigesada K, van de Sluis B, Liu PP. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MYH11. Oncogene. 2004;23:4297–307.CrossRefPubMed
22.
Zurück zum Zitat Coleman WB, Tsongalis GJ, editors. Molecular diagnostics: for the clinical laboratorian. 2nd ed. Totowa: Humana Press; 2006. Coleman WB, Tsongalis GJ, editors. Molecular diagnostics: for the clinical laboratorian. 2nd ed. Totowa: Humana Press; 2006.
23.
Zurück zum Zitat Zahedipour F, Ranjbaran R, Behbahani AB, Afshari KT, Okhovat MA, Tamadon G, et al. Development of flow cytometry-fluorescent in situ hybridization (flow-FISH) method for detection of PML/RARa chromosomal translocation in acute promyelocytic leukemia cell line. Avicenna J Med Biotech. 2017;9:104–8. Zahedipour F, Ranjbaran R, Behbahani AB, Afshari KT, Okhovat MA, Tamadon G, et al. Development of flow cytometry-fluorescent in situ hybridization (flow-FISH) method for detection of PML/RARa chromosomal translocation in acute promyelocytic leukemia cell line. Avicenna J Med Biotech. 2017;9:104–8.
24.
Zurück zum Zitat Tirado CA, Siangchin K, Shabsovich DS, Sharifian M, Schiller G. A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature. Biomark Res. 2016;4:1–8.CrossRef Tirado CA, Siangchin K, Shabsovich DS, Sharifian M, Schiller G. A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: a case report and a review of the literature. Biomark Res. 2016;4:1–8.CrossRef
25.
Zurück zum Zitat Coleman JF, Theil KS, Tubbs RR, Cook JR. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases. Am J Clin Pathol. 2011;135:915–20.CrossRefPubMed Coleman JF, Theil KS, Tubbs RR, Cook JR. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases. Am J Clin Pathol. 2011;135:915–20.CrossRefPubMed
26.
Zurück zum Zitat Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.CrossRefPubMedPubMedCentral Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–9.CrossRefPubMedPubMedCentral Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–9.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Verstovsek S, Tefferi A, editors. Myeloproliferative neoplasms. New York City: Humana Press; 2011. Verstovsek S, Tefferi A, editors. Myeloproliferative neoplasms. New York City: Humana Press; 2011.
Metadaten
Titel
Diagnostic and Prognostic Utility of Fluorescence In situ Hybridization (FISH) Analysis in Acute Myeloid Leukemia
verfasst von
Patrick R. Gonzales
Fady M. Mikhail
Publikationsdatum
24.10.2017
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 6/2017
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0426-6

Weitere Artikel der Ausgabe 6/2017

Current Hematologic Malignancy Reports 6/2017 Zur Ausgabe

CART and Immunotherapy (M Ruella, Section Editor)

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer

Acute Myeloid Leukemias (H Erba, Section Editor)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Using Social Media at National Meetings in Hematology—Optimal Use, Tips, Strategies, and Limitations

Acute Myeloid Leukemias (H Erba, Section Editor)

Methods of Detection of Measurable Residual Disease in AML

Acute Myeloid Leukemias (H Erba, Section Editor)

Predicting Chemotherapy Resistance in AML

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.